2024
Prospective REALITI-A study: 2-year real-world benefits of mepolizumab in severe asthma
Caruso C, Canonica G, Patel M, Smith A, Liu M, Alfonso-Cristancho R, Price R, Jakes R, Demetriou L, Valero A, Köhler T, Pilette C, Chupp G, Brusselle G, Howarth P. Prospective REALITI-A study: 2-year real-world benefits of mepolizumab in severe asthma. CHEST Pulmonary 2024, 100107. DOI: 10.1016/j.chpulm.2024.100107.Peer-Reviewed Original ResearchFollow-up periodMepolizumab treatmentAdverse eventsSevere asthmaRate of clinically significant asthma exacerbationsFollow-upMonoclonal antibodies targeting interleukin-5Clinically significant asthma exacerbationsMaintenance oral corticosteroidsAssociated with sustained reductionsProportion of patientsACQ-5 scoresAsthma Control QuestionnaireForced expiratory volumeOral corticosteroidsWell-toleratedACQ-5Clinical benefitMepolizumabProspective studyWeeks 0Asthma exacerbationsInterleukin-5Expiratory volumeSustained reductionActivated sputum eosinophils associated with exacerbations in children on mepolizumab
Wilson G, Knight J, Liu Q, Shelar A, Stewart E, Wang X, Yan X, Sanders J, Visness C, Gill M, Gruchalla R, Liu A, Kattan M, Khurana Hershey G, Togias A, Becker P, Altman M, Busse W, Jackson D, Montgomery R, Chupp G. Activated sputum eosinophils associated with exacerbations in children on mepolizumab. Journal Of Allergy And Clinical Immunology 2024, 154: 297-307.e13. PMID: 38485057, PMCID: PMC11305967, DOI: 10.1016/j.jaci.2024.01.031.Peer-Reviewed Original ResearchAirway eosinophilsSputum eosinophilsPatients treated with mepolizumabPlacebo-controlled clinical trialAnti-IL-5 treatmentEffect of mepolizumabEosinophil subpopulationsSevere eosinophilic asthmaAnti-interleukin-5Expression of CD62LFrequency of exacerbationsEosinophilic asthmaActivation markersSputum samplesUnsupervised cluster analysisMepolizumabTreatment armsReduce exacerbationsCD62LClinical trialsExacerbationMass cytometryEosinophilsExacerbation riskIntracellular markers
2023
Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps
Chupp G, Alobid I, Lugogo N, Kariyawasam H, Bourdin A, Chaker A, Smith S, Sousa A, Mayer B, Chan R, Matucci A. Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps. The Journal Of Allergy And Clinical Immunology In Practice 2023, 11: 3504-3512.e2. PMID: 37586475, DOI: 10.1016/j.jaip.2023.08.015.Peer-Reviewed Original ResearchConceptsSevere chronic rhinosinusitisOral corticosteroid doseSystemic corticosteroidsNasal polypsChronic rhinosinusitisCorticosteroid doseSinus surgerySCS useTreatment responseLong-term adverse effectsPlacebo treatment responsePrior sinus surgeryPatient baseline characteristicsBlood eosinophil countsSystemic corticosteroid useMepolizumab efficacyCorticosteroid useWeek 52Baseline characteristicsEosinophil countClinical benefitCare treatmentMepolizumabRhinosinusitisPlaceboReal-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study
Chupp G, Heaney L, Price R, Brusselle G, Gardiner F, Raimondi A, Chaudhuri R, Howarth P. Real-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study. Journal Of Allergy And Clinical Immunology 2023, 151: ab20. DOI: 10.1016/j.jaci.2022.12.066.Peer-Reviewed Original Research
2022
Mepolizumab Demonstrates Real-world Clinical Effectiveness in both Type 2 Biomarker High and Type 2 Biomarker Low Patients with Severe Asthma
Chupp G, Lee J, Liu M, Schleich F, Heaney L, Ribas C, Carrillo-Díaz T, Aparicio M, Moragón E, Sanchez-Herrero M, Gardiner F, Alfonso-Cristancho R, Jakes R, Price R, Howarth P. Mepolizumab Demonstrates Real-world Clinical Effectiveness in both Type 2 Biomarker High and Type 2 Biomarker Low Patients with Severe Asthma. Journal Of Allergy And Clinical Immunology 2022, 149: ab318. DOI: 10.1016/j.jaci.2021.12.019.Peer-Reviewed Original Research
2017
Mepolizumab Improves Lung Function and Exacerbation Rates in Severe Eosinophilic Asthma: The Musca Study - a Phase IIIb Randomized, Placebo-Controlled Tria
Trevor J, Bradford E, Albers F, Bratton D, Wang-Jairaj J, Nelsen L, Chupp G, Magnan A, Brinke A. Mepolizumab Improves Lung Function and Exacerbation Rates in Severe Eosinophilic Asthma: The Musca Study - a Phase IIIb Randomized, Placebo-Controlled Tria. Journal Of Allergy And Clinical Immunology 2017, 139: ab380. DOI: 10.1016/j.jaci.2016.12.912.Peer-Reviewed Original ResearchMepolizumab Significantly Improves Health Status and Asthma Control in Severe Eosinophilic Asthma: The Musca Study - a Phase IIIb Randomized, Placebo-Controlled Trial
Chupp G, Bradford E, Albers F, Bratton D, Wang-Jairaj J, Nelsen L, Trevor J, Magnan A, Brinke A. Mepolizumab Significantly Improves Health Status and Asthma Control in Severe Eosinophilic Asthma: The Musca Study - a Phase IIIb Randomized, Placebo-Controlled Trial. Journal Of Allergy And Clinical Immunology 2017, 139: ab380. DOI: 10.1016/j.jaci.2016.12.911.Peer-Reviewed Original Research